EQL Pharma AB (publ) (STO:EQL)

Market Cap	2.23B
Revenue (ttm)	338.39M
Net Income (ttm)	34.73M
Shares Out	29.06M
EPS (ttm)	1.19
PE Ratio	64.50
Forward PE	33.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,246
Average Volume	18,501
Open	70.40
Previous Close	70.40
Day's Range	69.92 - 72.07
52-Week Range	32.10 - 77.00
Beta	0.72
RSI	46.96
Earnings Date	May 8, 2025

About EQL Pharma AB

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 21
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: EQL

Financial Performance

In 2023, EQL Pharma AB's revenue was 264.17 million, an increase of 1.64% compared to the previous year's 259.91 million. Earnings were 22.71 million, a decrease of -26.57%.